XML 20 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Oct. 30, 2016
Nov. 01, 2015
Cash flows from operating activities:    
Net earnings $ 160,760 $ 168,940
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities:    
Depreciation and amortization 127,745 125,093
Loss on disposal/impairment of assets 1,852 3,558
Amortization of deferred lease incentives (18,789) (18,326)
Deferred income taxes (14,461) (13,526)
Tax benefit related to stock-based awards 23,571 29,603
Excess tax benefit related to stock-based awards (4,817) (14,283)
Stock-based compensation expense 37,975 36,182
Other (647) 91
Changes in:    
Accounts receivable (17,400) (21,875)
Merchandise inventories (82,410) (216,294)
Prepaid catalog expenses 3,591 (1,820)
Prepaid expenses and other assets (29,205) (20,909)
Accounts payable (17,403) (10,179)
Accrued salaries, benefits and other current and long-term liabilities (507) (13,494)
Customer deposits (7,445) 32,016
Deferred rent and lease incentives 25,969 25,561
Income taxes payable (65,915) 2,707
Net cash provided by operating activities 122,464 93,045
Cash flows from investing activities:    
Purchases of property and equipment (127,169) (136,069)
Other 370 535
Net cash used in investing activities (126,799) (135,534)
Cash flows from financing activities:    
Borrowings under revolving line of credit 125,000 200,000
Repurchase of common stock (115,167) (196,497)
Payment of dividends (100,854) (96,020)
Tax withholdings related to stock-based awards (26,518) (31,019)
Excess tax benefit related to stock-based awards 4,817 14,283
Proceeds related to stock-based awards 1,532 2,647
Repayment of long-term obligations   (1,968)
Other (48)  
Net cash used in financing activities (111,238) (108,574)
Effect of exchange rates on cash and cash equivalents (2,693) 400
Net decrease in cash and cash equivalents (118,266) (150,663)
Cash and cash equivalents at beginning of period 193,647 222,927
Cash and cash equivalents at end of period $ 75,381 $ 72,264